Skip to main content
Shilpa Medicare Ltd. logo

Shilpa Medicare Ltd. — Investor Relations & Filings

Ticker · SHILPAMED ISIN · INE790G01031 LEI · 3358002PKUL8S2RNJO60 BSE.NS Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2026-05-22 Board/Management Inform…
Country IN India
Listing BSE.NS SHILPAMED

About Shilpa Medicare Ltd.

https://vbshilpa.com/

Shilpa Medicare Ltd. is a research-led organization specializing in the development, manufacture, and commercialization of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the oncology segment, producing a wide range of high-potency anti-cancer drugs. Its capabilities extend to diverse therapeutic areas, including ophthalmology, dermatology, and biosimilars. Shilpa Medicare operates manufacturing facilities compliant with international regulatory standards such as the USFDA and EU-GMP. The organization emphasizes complex chemistry and advanced drug delivery systems, offering a portfolio that includes oral solids, injectables, and transdermal patches. Through its R&D infrastructure, the company provides contract research and manufacturing services to global partners, supporting the lifecycle of generic and innovative pharmaceutical products.

Recent filings

Filing Released Lang Actions
Dividend
Board/Management Information Classification · 92% confidence The document is an official notification to stock exchanges under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 about the outcome of the Board Meeting held on 22 May 2026. It lists board approvals and decisions including audited financial results, dividend recommendation, auditor appointments, office relocation, and investments. This is clearly a Board/Management Information announcement under Regulation 30, not the actual annual report or financial statements themselves. Therefore, it falls under the category of Board/Management Information (MANG).
2026-05-22 English
Outcome of the Board Meeting
Regulatory Filings Classification · 78% confidence The document is an SEBI Listing Regulation disclosure titled “Outcome of the Board Meeting” filed with BSE/NSE. It announces audited financial results, dividend recommendations, auditor appointments, office-shift resolutions, a postal ballot notice, acquisitions, and includes the independent auditor’s report. It is not a full Annual Report (10-K), not a simple earnings highlights press release (ER), and not solely an audit report (AR). It is a regulatory announcement under Listing Obligations and Disclosure Requirements and thus best fits the general Regulatory Filings category (RNS).
2026-05-22 English
Financial Results
Regulatory Filings Classification · 85% confidence The document is the official "Outcome of the Board Meeting" notice filed under SEBI (Listing Obligations & Disclosure Requirements) Regulations. It covers multiple corporate events (approval of audited financial results, dividend recommendation, auditor appointments, office relocation, acquisitions, etc.) and is addressed to stock exchanges as a regulatory disclosure. It is not itself the full Annual Report (10-K) or an Interim Report, nor is it a standalone earnings release (ER) limited to key highlights. This broad regulatory announcement falls under the general Regulatory Filings category (RNS).
2026-05-22 English
Outcome of Board Meeting
Regulatory Filings Classification · 82% confidence The document is a formal corporate filing under SEBI (Listing Obligations and Disclosure Requirements) Regulations, disclosing the outcome of the board meeting including approval of audited financial results, auditor’s report, dividend recommendation, auditor appointments, office shifts, acquisition details, and annexures. It does not represent a full annual report (10-K) or interim financial report itself, nor is it solely an audit report, earnings release or proxy statement. Instead, it is a general regulatory announcement of multiple corporate actions under Reg. 30, 33 & 43, making it a Regulatory Filing (RNS).
2026-05-22 English
The schedule of Q4- FY26 Earnings Conference Call, which is to be held on Friday, May 22, 2025, at 16.00 hrs.
Regulatory Filings Classification · 86% confidence The document is an SEBI (Listing Obligations and Disclosure Requirements) Regulation 30(2) filing notifying stock exchanges of the schedule for the 4Q FY26 earnings conference call. It contains no financial results or substantive statements — only the details of the earnings call logistics and a link to the investor presentation. This is a general regulatory announcement (disclosure) under Indian listing rules rather than the actual earnings release, call transcript, or an AR/IR report. Therefore, the correct category is the catch-all Regulatory Filings (RNS).
2026-05-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 72% confidence The document is an exchange filing under SEBI LODR Regulation 30(2) notifying the stock exchanges of the schedule for the Q4 FY26 earnings conference call. It is not the earnings release or financial statements themselves, nor a transcript or investor presentation. It is a required regulatory disclosure rather than the content of a report, making it a general regulatory filing.
2026-05-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.